Immunogenicity of Novel Mumps Vaccine Candidates Generated by Genetic Modification

March 24, 2014

(JOURNAL OF VIROLOGY)– Mumps is a highly contagious human disease, characterized by lateral or bilateral nonsuppurative swelling of the parotid glands and neurological complications that can result in aseptic meningitis or encephalitis. A mumps vaccination program implemented since the 1960s reduced mumps incidence by more than 99% and kept the mumps case numbers as low as hundreds of cases per year in the United States before 2006. However, a large mumps outbreak occurred in vaccinated populations in 2006 and again in 2009 in the United States, raising concerns about the efficacy of the vaccination program.

images (5)Previously, we have shown that clinical isolate-based recombinant mumps viruses lacking expression of either the V protein (rMuVΔV) or the SH protein (rMuVΔSH) are attenuated in a neurovirulence test using newborn rat brains (P. Xu et al., Virology 417:126–136, 2011,; P. Xu et al., J. Virol. 86:1768–1776, 2012, and may be good candidates for vaccine development. In this study, we examined immunity induced by rMuVΔSH and rMuVΔV in mice. Furthermore, we generated recombinant mumps viruses lacking expression of both the V protein and the SH protein (rMuVΔSHΔV). Analysis of rMuVΔSHΔV indicated that it was stable in tissue culture cell lines. Importantly, rMuVΔSHΔV was immunogenic in mice, indicating that it is a promising candidate for mumps vaccine development.

  1. 1.   Pei Xua,b,
  2. 2.   Zhenhai Chena,
  3. 3.   Shannon Phana,
  4. 4.   Adrian Pickara and
  5. 5.   Biao Hea
  6. 1.    aDepartment of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, Georgia, USA
  7. 2.    bIntercollege Graduate Program in Cell and Developmental Biology, Pennsylvania State University, University Park, Pennsylvania, USA